Saurashtra News

Delveinsight Business Research LLP

The Multiple Myeloma Pipeline report embraces in-depth commercial and clinical assessment of the Multiple Myeloma pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multiple Myeloma collaborations, mergers, acquisition, funding, designations, and other product-related details.

The dynamics of the Multiple Myeloma market is anticipated to change in the coming years owing to the launch of novel drugs and the rise in healthcare spending across the world. 

Key companies in the Multiple Myeloma therapeutics domain includes:

• Pfizer

• Takeda

• Amgen

• Abbvie

• AbbVie

• Roche

• AstraZeneca

• GlaxoSmithKline

• Bristol-Myers Squibb

• Janssen Research & Development

• Merck Sharp & Dohme Corp.

And many others.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight

Multiple Myeloma Pipeline Analysis

The report provides insights into: 

• The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Myeloma with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Multiple Myeloma Treatment.

• Multiple Myeloma key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Myeloma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

The Multiple Myeloma market size is expected to increase during the forecast period owing to the increasing incidence of Multiple Myeloma, label expansion of current therapies, and the rising awareness of marketed therapies.

Multiple Myeloma Therapies covered in the report include:

• Descartes-11

• Venetoclax

• REGN5458

• Iberdomide

• Imfinzi (Durvalumab;MEDI4736)

• Braftovi (encorafenib)

• Motixafortide (BL-8040)

• Felzartamab (MOR202)

• Chidamide (Epidaza)

• Keytruda (Pembrolizumab)

• Cetrelimab (JNJ-63723283)

• Ciltacabtagene Autoleucel (cilta-cel/JNJ-68284528/LCAR-B38M)

And many more.

Request for Sample @ Multiple Myeloma Novel Therapies And Emerging Technologies

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Multiple Myeloma.    

• In the coming years, the Multiple Myeloma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 

• The companies and academics are working to assess challenges and seek opportunities that could influence Multiple Myeloma Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the Multiple Myeloma treatment market. Several potential therapies for Multiple Myeloma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Multiple Myeloma market size in the coming years.  

• Our in-depth analysis of the Multiple Myeloma pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

Table of Content

1. Report Introduction

2. Multiple Myeloma 

3. Multiple Myeloma Current Treatment Patterns

4. Multiple Myeloma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Multiple Myeloma Late Stage Products (Phase-III)

7. Multiple Myeloma Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Multiple Myeloma Discontinued Products

13. Multiple Myeloma Product Profiles

14. Multiple Myeloma Key Companies

15. Multiple Myeloma Key Products

16. Dormant and Discontinued Products

17. Multiple Myeloma Unmet Needs

18. Multiple Myeloma Future Perspectives

19. Multiple Myeloma Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight

Latest Reports By DelveInsight

Multiple Myeloma Market Insight

DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Multiple Myeloma market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Healthcare Blogs 

Pharma Companies in Autoimmune Diseases

Autoimmune Diseases encompass more than 100+ diseases and are also responsible for multiple life-threatening complications. The prevalence is increasing at par with diseases such as heart disease and cancer. Autoimmune Diseases are mounting a significant burden on the healthcare infrastructure and the affected person. However, to deal with the rising prevalence, companies such as GSK, R-Pharm, Provention Bio, Tolerion, AbbVie, Gilead Sciences, AstraZeneca, and several others are diligently focussing to offer potential new treatment options.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/